Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Molecules › Ribupatide (HRS9531)

Ribupatide (HRS9531)

GIP/GLP-1 · s.c. · Hengrui / Kailera

Data cut 12 November 2026 · page built 16 November 2026 · 16 trial arms · 7 trials with results · 15 registered trials · see on the pipeline board

Summary

Also known as
KAI-9531, Hengrui / Kailera
Mechanism
GIP/GLP-1
Route
s.c.
Company
Hengrui / Kailera
Highest development stage
filed
Status (as of data cut)
Phase 3 positive in China (GEMINI-1: −17.7 % TP / −19.2 % at 48 weeks); NDA accepted in China (Sep 2025); global phase 3 KaiNETIC enrolled (Kailera) verify
Next milestone
China approval; KaiNETIC topline mid-2028

Indications: regulatory and evidence status

IndicationCodeStatusEvidence
Obesity3 positive phase 3Positive phase 3 in China (GEMINI-1); NDA accepted Sep 2025Hengrui NDA announcement (SSE, Sep 2025)
T2D3 positive phase 3Positive phase 3 versus semaglutide (HbA1c −2.78 vs −2.29 %)
CV outcomes2 phase 3 ongoingPhase 3 ongoing
CKD0 no data
HFpEF1 phase 2 / signalPhase 2 only
MASH1 phase 2 / signalPhase 2 only
Sleep apnoea2 phase 3 ongoingPhase 3 ongoing
Knee OA2 phase 3 ongoingPhase 3 ongoing
Alzheimer's0 no data

4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.

Trial arms: weight, HbA1c and tolerability

TrialArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
HRS9531-201 (NCT05881837)1.0 mgobesity china24249—−5.4 % vs −0.1 %
Δ −5.3 pp
—2.0 vs 2.0—14.3 vs 8.26.1 vs 2.0——congress
HRS9531-201 (NCT05881837)3.0 mgobesity china24249—−13.4 % vs −0.1 %
Δ −13.3 pp
—2.0 vs 2.0—27.5 vs 8.219.6 vs 2.0——congress
HRS9531-201 (NCT05881837)4.5 mgobesity china24249—−14.0 % vs −0.1 %
Δ −13.9 pp
—0.0 vs 2.0—32.0 vs 8.220.0 vs 2.0——congress
HRS9531-201 (NCT05881837)6.0 mgobesity china24249—−16.8 % vs −0.1 %
Δ −16.7 pp
—0.0 vs 2.0—32.7 vs 8.228.6 vs 2.0——congress
HRS9531-203 (NCT06054698)8 mgobesity china36—−23.6 %−22.8 %———————press release
HRS9531-T-201 oral ribupatide (NCT06841445)10 mg oral QDobesity china26166−6.9 % vs −2.3 %
Δ −4.6 pp
−6.7 % vs −2.1 %
Δ −4.6 pp
—0.0 vs 0.0—11.9 vs 7.52.4 vs 0.02.4 vs 2.5−6.1 vs −3.9press release
HRS9531-T-201 oral ribupatide (NCT06841445)25 mg oral QDobesity china26166−12.1 % vs −2.3 %
Δ −9.8 pp
−11.9 % vs −2.1 %
Δ −9.8 pp
—0.0 vs 0.0—22.7 vs 7.511.4 vs 0.04.5 vs 2.5−6.4 vs −3.9press release
HRS9531-T-201 oral ribupatide (NCT06841445)50 mg oral QDobesity china26166−12.1 % vs −2.3 %
Δ −9.8 pp
−11.4 % vs −2.1 %
Δ −9.3 pp
—2.5 vs 0.0—20.0 vs 7.57.5 vs 0.00.0 vs 2.5−5.1 vs −3.9press release
Ribupatide in obesity + PMOS (NCT06595797)1 mgobesity china32158—−10.0 % vs −2.6 %
Δ −7.4 pp
—0.0 vs 0.0———0.0 vs 0.0—congress
Ribupatide phase 2 (obesity + PMOS)ribupatide 4 mgobesity china32158—−20.2 % vs −2.6 %
Δ −17.6 pp
—0.0 vs 0.0———0.0 vs 0.0—verified
Ribupatide phase 2 (obesity + PMOS)ribupatide 2 mgobesity china32158—−15.1 % vs −2.6 %
Δ −12.5 pp
—0.0 vs 0.0———0.0 vs 0.0—verified
HRS9531-301 (GEMINI-1, NCT06396429)2 mgobesity china48567−11.2 % vs −1.4 %
Δ −9.8 pp
−10.7 % vs −1.4 %
Δ −9.3 pp
—0.7 vs 0.0—16.2 vs 4.914.1 vs 2.11.4 vs 5.6—press release
HRS9531-301 (GEMINI-1, NCT06396429)4 mgobesity china48567−17.4 % vs −1.4 %
Δ −16.0 pp
−16.4 % vs −1.4 %
Δ −15.0 pp
—0.7 vs 0.0—17.0 vs 4.919.1 vs 2.15.0 vs 5.6—press release
HRS9531-301 (GEMINI-1, NCT06396429)6 mgobesity china48567−19.2 % vs −1.4 %
Δ −17.8 pp
−17.7 % vs −1.4 %
Δ −16.3 pp
—1.4 vs 0.0—27.0 vs 4.924.1 vs 2.14.3 vs 5.6—press release
Ribupatide T2D phase 3 after metformin +/- SGLT2i (NCT06649344)4 mg vs semaglutide 1 mg: HbA1c -2.29t2d china36———−2.8——————press release
Ribupatide T2D phase 3 after metformin +/- SGLT2i (NCT06649344)2 mg vs semaglutide 1 mg: HbA1c -2.29t2d china36———−2.3——————press release

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Notes

Verbatim quotes from the source (68)
  • ribupatide 4 mg · weight_tp · Results
    the least-squares (LS) mean percentage weight change was -10.0%, -15.1% and -20.2% for the ribupatide 1 mg, 2 mg and 4 mg, respectively, versus -2.6% with placebo
  • ribupatide 4 mg · ae_dc · Results
    No serious AEs, adverse events of special interest (AESI) or AEs leading to treatment discontinuation occurred.
  • ribupatide 4 mg · sae · Results
    No serious AEs, adverse events of special interest (AESI) or AEs leading to treatment discontinuation occurred.
  • ribupatide 2 mg · weight_tp · Results
    the least-squares (LS) mean percentage weight change was -10.0%, -15.1% and -20.2% for the ribupatide 1 mg, 2 mg and 4 mg, respectively, versus -2.6% with placebo
  • ribupatide 2 mg · ae_dc · Results
    No serious AEs, adverse events of special interest (AESI) or AEs leading to treatment discontinuation occurred.
  • ribupatide 2 mg · sae · Results
    No serious AEs, adverse events of special interest (AESI) or AEs leading to treatment discontinuation occurred.
  • 2 mg · weight_tp · press release
    Based on the treatment policy estimand^II, participants taking HRS9531 achieved a mean weight loss of 10.7% (2 mg), 16.4% (4 mg) and 17.7% (6 mg), compared to placebo (1.4%).
  • 2 mg · ae_dc · press release
    Permanent treatment discontinuation rates due to TEAEs were very low with 0.7% (1 participant, 2 mg), 0.7% (1 participant, 4 mg), 1.4% (2 participants, 6 mg) and 0% (placebo).
  • 2 mg · nausea · abstract
    Nausea 7 (4.9) 23 (16.2) 24 (17.0) 38 (27.0)
  • 2 mg · vomiting · abstract
    Vomiting 3 (2.1) 20 (14.1) 27 (19.1) 34 (24.1)
  • 2 mg · sae · abstract
    SAEs 8 (5.6) 2 (1.4) 7 (5.0) 6 (4.3)
  • 2 mg · weight_eff · press release
    Based on the hypothetical strategy estimand^I, participants taking HRS9531 achieved a mean weight loss of 11.2% (2 mg), 17.4% (4 mg) and 19.2% (6 mg), compared to placebo (1.4%).
  • 4 mg · weight_tp · press release
    Based on the treatment policy estimand^II, participants taking HRS9531 achieved a mean weight loss of 10.7% (2 mg), 16.4% (4 mg) and 17.7% (6 mg), compared to placebo (1.4%).
  • 4 mg · ae_dc · press release
    Permanent treatment discontinuation rates due to TEAEs were very low with 0.7% (1 participant, 2 mg), 0.7% (1 participant, 4 mg), 1.4% (2 participants, 6 mg) and 0% (placebo).
  • 4 mg · nausea · abstract
    Nausea 7 (4.9) 23 (16.2) 24 (17.0) 38 (27.0)
  • 4 mg · vomiting · abstract
    Vomiting 3 (2.1) 20 (14.1) 27 (19.1) 34 (24.1)
  • 4 mg · sae · abstract
    SAEs 8 (5.6) 2 (1.4) 7 (5.0) 6 (4.3)
  • 4 mg · weight_eff · press release
    Based on the hypothetical strategy estimand^I, participants taking HRS9531 achieved a mean weight loss of 11.2% (2 mg), 17.4% (4 mg) and 19.2% (6 mg), compared to placebo (1.4%).
  • 6 mg · weight_tp · press release
    Based on the treatment policy estimand^II, participants taking HRS9531 achieved a mean weight loss of 10.7% (2 mg), 16.4% (4 mg) and 17.7% (6 mg), compared to placebo (1.4%).
  • 6 mg · ae_dc · press release
    Permanent treatment discontinuation rates due to TEAEs were very low with 0.7% (1 participant, 2 mg), 0.7% (1 participant, 4 mg), 1.4% (2 participants, 6 mg) and 0% (placebo).
  • 6 mg · nausea · abstract
    Nausea 7 (4.9) 23 (16.2) 24 (17.0) 38 (27.0)
  • 6 mg · vomiting · abstract
    Vomiting 3 (2.1) 20 (14.1) 27 (19.1) 34 (24.1)
  • 6 mg · sae · abstract
    SAEs 8 (5.6) 2 (1.4) 7 (5.0) 6 (4.3)
  • 6 mg · weight_eff · press release
    Based on the hypothetical strategy estimand^I, participants taking HRS9531 achieved a mean weight loss of 11.2% (2 mg), 17.4% (4 mg) and 19.2% (6 mg), compared to placebo (1.4%).
  • 8 mg · weight_tp · press release
    participants taking the 8 mg dose of HRS9531 achieved a mean weight loss of 22.8% (21.1% placebo-adjusted) at week 36
  • 8 mg · weight_eff · press release
    mean weight loss with the 8 mg dose of HRS9531 was 23.6% (21.7% placebo-adjusted)
  • 1.0 mg · weight_tp · abstract
    in body weight was -5.4% (95% CI -7.3% to -3.5%), -13.4% (-15.2% to -
  • 1.0 mg · nausea · abstract
    Nausea 7 (14.3) 14 (27.5) 16 (32.0) 16 (32.7) 4 (8.2)
  • 1.0 mg · vomiting · abstract
    Vomiting 3 (6.1) 10 (19.6) 10 (20.0) 14 (28.6) 1 (2.0)
  • 1.0 mg · ae_dc · Table 3 (Adverse events), columns 1.0/3.0/4.5/6.0 mg/placebo
    1 (2.0) 1 (2.0) 0 0 1 (2.0)
  • 3.0 mg · weight_tp · abstract
    in body weight was -5.4% (95% CI -7.3% to -3.5%), -13.4% (-15.2% to -
  • 3.0 mg · nausea · abstract
    Nausea 7 (14.3) 14 (27.5) 16 (32.0) 16 (32.7) 4 (8.2)
  • 3.0 mg · vomiting · abstract
    Vomiting 3 (6.1) 10 (19.6) 10 (20.0) 14 (28.6) 1 (2.0)
  • 3.0 mg · ae_dc · Table 3 (Adverse events), columns 1.0/3.0/4.5/6.0 mg/placebo
    1 (2.0) 1 (2.0) 0 0 1 (2.0)
  • 4.5 mg · weight_tp · abstract
    11.5%), -14.0% (-15.9% to -12.1%), and -16.8% (-18.8% to -14.9%) in the
  • 4.5 mg · nausea · abstract
    Nausea 7 (14.3) 14 (27.5) 16 (32.0) 16 (32.7) 4 (8.2)
  • 4.5 mg · vomiting · abstract
    Vomiting 3 (6.1) 10 (19.6) 10 (20.0) 14 (28.6) 1 (2.0)
  • 4.5 mg · ae_dc · Table 3 (Adverse events), columns 1.0/3.0/4.5/6.0 mg/placebo
    1 (2.0) 1 (2.0) 0 0 1 (2.0)
  • 6.0 mg · weight_tp · abstract
    11.5%), -14.0% (-15.9% to -12.1%), and -16.8% (-18.8% to -14.9%) in the
  • 6.0 mg · nausea · abstract
    Nausea 7 (14.3) 14 (27.5) 16 (32.0) 16 (32.7) 4 (8.2)
  • 6.0 mg · vomiting · abstract
    Vomiting 3 (6.1) 10 (19.6) 10 (20.0) 14 (28.6) 1 (2.0)
  • 6.0 mg · ae_dc · Table 3 (Adverse events), columns 1.0/3.0/4.5/6.0 mg/placebo
    1 (2.0) 1 (2.0) 0 0 1 (2.0)
  • 10 mg oral QD · weight_tp · press release
    Based on the treatment policy estimand^II at Week 26, participants taking oral ribupatide achieved a mean weight loss of 6.7% (10 mg), 11.9% (25 mg), and 11.4% (50 mg)
  • 10 mg oral QD · nausea · abstract
    Nausea 5 (11.9) 10 (22.7) 8 (20.0) 3 (7.5)
  • 10 mg oral QD · vomiting · abstract
    Vomiting 1 (2.4) 5 (11.4) 3 (7.5) 0
  • 10 mg oral QD · sae · abstract
    SAEs* 1 (2.4) 2 (4.5) 0 1 (2.5)
  • 10 mg oral QD · ae_dc · abstract
    TEAEs leading to treatment discontinuation 0 0 1 (2.5)# 0
  • 10 mg oral QD · sbp · abstract
    SBP, mmHg, LS mean (SE) -6.1 (1.4) -6.4 (1.3) -5.1 (1.4) -3.9 (1.5)
  • 10 mg oral QD · weight_eff · press release
    Based on the efficacy estimand^I at Week 26, participants taking oral ribupatide achieved a mean weight loss of 6.9% (10 mg), 12.1% (25 mg), and 12.1% (50 mg)
  • 25 mg oral QD · weight_tp · press release
    Based on the treatment policy estimand^II at Week 26, participants taking oral ribupatide achieved a mean weight loss of 6.7% (10 mg), 11.9% (25 mg), and 11.4% (50 mg)
  • 25 mg oral QD · nausea · abstract
    Nausea 5 (11.9) 10 (22.7) 8 (20.0) 3 (7.5)
  • 25 mg oral QD · vomiting · abstract
    Vomiting 1 (2.4) 5 (11.4) 3 (7.5) 0
  • 25 mg oral QD · sae · abstract
    SAEs* 1 (2.4) 2 (4.5) 0 1 (2.5)
  • 25 mg oral QD · ae_dc · abstract
    TEAEs leading to treatment discontinuation 0 0 1 (2.5)# 0
  • 25 mg oral QD · sbp · abstract
    SBP, mmHg, LS mean (SE) -6.1 (1.4) -6.4 (1.3) -5.1 (1.4) -3.9 (1.5)
  • 25 mg oral QD · weight_eff · press release
    Based on the efficacy estimand^I at Week 26, participants taking oral ribupatide achieved a mean weight loss of 6.9% (10 mg), 12.1% (25 mg), and 12.1% (50 mg)
  • 50 mg oral QD · weight_tp · press release
    Based on the treatment policy estimand^II at Week 26, participants taking oral ribupatide achieved a mean weight loss of 6.7% (10 mg), 11.9% (25 mg), and 11.4% (50 mg)
  • 50 mg oral QD · nausea · abstract
    Nausea 5 (11.9) 10 (22.7) 8 (20.0) 3 (7.5)
  • 50 mg oral QD · vomiting · abstract
    Vomiting 1 (2.4) 5 (11.4) 3 (7.5) 0
  • 50 mg oral QD · sae · abstract
    SAEs* 1 (2.4) 2 (4.5) 0 1 (2.5)
  • 50 mg oral QD · ae_dc · abstract
    TEAEs leading to treatment discontinuation 0 0 1 (2.5)# 0
  • 50 mg oral QD · sbp · abstract
    SBP, mmHg, LS mean (SE) -6.1 (1.4) -6.4 (1.3) -5.1 (1.4) -3.9 (1.5)
  • 50 mg oral QD · weight_eff · press release
    Based on the efficacy estimand^I at Week 26, participants taking oral ribupatide achieved a mean weight loss of 6.9% (10 mg), 12.1% (25 mg), and 12.1% (50 mg)
  • 1 mg · weight_tp · abstract
    mean percentage weight change was -10.0%, -15.1% and -20.2% for the ribupatide 1
  • 1 mg · ae_dc · abstract, Results (last sentences)
    No serious AEs, adverse events of special interest (AESI) or AEs leading to treatment discontinuation occurred.
  • 1 mg · sae · abstract, Results (last sentences)
    No serious AEs, adverse events of special interest (AESI) or AEs leading to treatment discontinuation occurred.
  • 4 mg · hba1c · press release
    the mean HbA1c reductions in the ribupatide injection 4 mg and 2 mg groups reached 2.78% and 2.34%, respectively, compared to 2.29% in the semaglutide injection 1 mg group
  • 2 mg · hba1c · press release
    the mean HbA1c reductions in the ribupatide injection 4 mg and 2 mg groups reached 2.78% and 2.34%, respectively, compared to 2.29% in the semaglutide injection 1 mg group

Registered trials (15)

From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.

TrialIndicationPhaseStatusStart → primary completionnResultRegistry
NCT07670884
A Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese Subjects
ObesityPhase 3recruiting2026-07 → 2027-10675recruitingNCT07670884
NCT07709910
A Trial of Ribupatide Injection in Participants With Obesity and Knee Osteoarthritis
Knee OAPhase 3not yet recruiting2026-07 → 2028-11382not yet recruitingNCT07709910
ASCVD
A Phase III Study To Evaluate the Efficacy And Safety Of HRS9531 In Participants With Atherosclerotic Cardiovascular Disease
CV outcomesPhase 3recruiting2026-05 → 2031-059262recruitingNCT07551492
KaiNETIC-2
Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
ObesityPhase 3active not recruiting2026-01 → 2028-031270active not recruitingNCT07284901
KaiNETIC-1
Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
ObesityPhase 3active not recruiting2025-12 → 2028-022530active not recruitingNCT07284875
KaiNETIC-3
Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
ObesityPhase 3active not recruiting2025-12 → 2028-031270active not recruitingNCT07284979
NCT07285902
A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity
ObesityPhase 3active not recruiting2025-12 → 2027-03572active not recruitingNCT07285902
NCT06994650
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) Therapy
Sleep apnoeaPhase 3active not recruiting2025-08 → 2026-12144active not recruitingNCT06994650
NCT06974851
A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity
Sleep apnoeaPhase 3recruiting2025-07 → 2026-12140recruitingNCT06974851
NCT07060456
Efficacy and Safety of HRS9531 in Participants With Type 2 Diabetes Treated With Basal Insulin
T2DPhase 3recruiting2025-07 → 2027-02300recruitingNCT07060456
NCT06650007
the Efficacy and Safety of HRS9531 Injection in Subjects With Type 2 Diabetes, Inadequately Controlled With Diet and Exercise Alone
T2DPhase 3completed2024-11 → 2026-01218Completed; results not in the atlas yetNCT06650007
NCT06649344
A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes
T2DPhase 3completed2024-10 → 2026-07884Completed; results not in the atlas yetNCT06649344
NCT06565871
A Study of HRS9531 Injection in Obese Subjects With Obstructive Sleep Apnea
Sleep apnoeaPhase 2unknown2024-08 → 2025-12108unknownNCT06565871
NCT06391710
HRS9531 Injection in Obese Subjects With Heart Failure With Preserved Ejection Fraction
HFpEFPhase 2active not recruiting2024-05 → 2026-01203active not recruitingNCT06391710
NCT06396429
To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects With Overweight or Obese
ObesityPhase 3completed2024-05 → 2025-07567Completed; results not in the atlas yetNCT06396429

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: Ribupatide (HRS9531). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/ribupatide/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.